Female pattern hair loss (FPHL), also called androgenetic alopecia in women, is the most common cause of hair loss in adult women. Despite affecting an estimated 30–40% of women by age 50, it remains underdiagnosed — partly because it presents differently than male pattern baldness, and partly because women are often told their hair loss is "just stress" when the cause is actually hormonal and genetic.
What causes female pattern hair loss
The underlying mechanism of FPHL is the same as in men: dihydrotestosterone (DHT), a potent androgen, binds to receptors in genetically susceptible hair follicles and progressively miniaturizes them over successive hair cycles. What differs in women is the distribution and severity — and the fact that many women with FPHL have normal androgen levels on bloodwork. FPHL in women appears to involve heightened follicular sensitivity to androgens, not necessarily elevated androgen production.
Contributing factors include:
- Genetic predisposition: Family history on either parent's side significantly increases risk. Multiple genes are involved, making inheritance patterns complex.
- Hormonal shifts: Menopause, postpartum estrogen drop, and conditions like PCOS (polycystic ovary syndrome) that elevate androgens can trigger or accelerate FPHL.
- Age: FPHL becomes more prevalent with age, with prevalence increasing significantly after menopause as estrogen's protective effect on follicles diminishes.
How it presents differently from male pattern baldness
While male androgenetic alopecia typically follows the Norwood scale — characterized by recession at the temples and crown — female pattern hair loss presents as diffuse thinning across the central scalp. The Ludwig Scale (I–III) describes the progression: Stage I shows widening of the central part; Stage II shows more pronounced thinning across the crown; Stage III involves severe thinning with significant loss of density.
Crucially, the frontal hairline is usually preserved in FPHL — a distinguishing feature from male pattern loss and from other causes of frontal hair loss (like traction alopecia or frontal fibrosing alopecia). This preservation of the hairline often causes women to underestimate the severity of their loss, since the most visible reference point looks relatively intact.
Getting an accurate diagnosis
FPHL is a clinical diagnosis, but ruling out other causes is essential before starting treatment. Several conditions can cause or worsen diffuse hair thinning in women:
- Thyroid dysfunction (both hypothyroidism and hyperthyroidism) — TSH should be checked
- Iron deficiency — ferritin is the most sensitive marker; levels below 40 ng/mL can cause or worsen shedding
- PCOS — associated with elevated androgens and often presents with irregular periods, acne, or hirsutism alongside hair thinning
- Telogen effluvium — stress-induced diffuse shedding that can be confused with or layered on top of FPHL
A licensed provider may also use dermoscopy or trichoscopy to assess hair caliber, follicular density, and miniaturization pattern to confirm the diagnosis.
Treatment options with clinical evidence
Topical minoxidil (2–10%): The most established first-line treatment for FPHL. Prolongs anagen phase and improves follicle miniaturization. Efficacy is influenced significantly by SULT1A1 enzyme activity. Compounded formulations allow for higher concentrations and vehicle customization.
Oral minoxidil (0.625–2.5 mg/day): Increasingly used for women, particularly those with low SULT1A1 activity or insufficient response to topical formulations. Low-dose oral minoxidil has a strong safety profile and bypasses the topical conversion step entirely.
Spironolactone (25–200 mg/day): An aldosterone antagonist with anti-androgenic properties. Widely used off-label for women with FPHL, particularly those with elevated androgens or PCOS. Requires blood pressure monitoring and contraception in premenopausal women due to potential fetal effects.
Finasteride / Dutasteride: 5-alpha reductase inhibitors that block DHT. More commonly prescribed for men, but used in postmenopausal women with androgenetic alopecia under clinician supervision. Contraindicated in women of childbearing potential due to teratogenic risk.
Combination therapy: For women with moderate to advanced FPHL, combination of minoxidil with an anti-androgen (spironolactone or low-dose finasteride in appropriate candidates) typically produces better results than either treatment alone.
This content is for informational purposes only. Consult a licensed provider before starting any treatment.